ValGenesis and Zamann have partnered to provide customers in life sciences and other highly regulated industries across Europe.
News
News
_________________
ValGenesis Successfully Showcased the Transformative Power of Its Platform Through New Product Announcements and Customer Case Studies at ValConnect 2024
June 26, 2024 | The ValConnect conference, in Lisbon was a great success, with an excellent line-up of new releases and customer success stories for partners, customers, and industry experts.
2024
June
Célere partners with life sciences and healthcare institutions to help them improve operational performance and regulatory compliance through digitized cGMP facilities, cGxP CSV.
ValGenesis Inc. announced the launch of VLMS 5.0, the new version of its flagship digital validation lifecycle management software poised to transform the industry's approach to digital transformation.
May
ValGenesis and Autocal have strengthened their capabilities to assist life sciences companies in India meet stringent regulatory requirements for quality and safety in drug development
A global science and technology company selected ValGenesis VLMS to digitize the computer system validation process across its manufacturing sites.
ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS) will unveil the next version of VLMS and an enhanced portfolio of cutting-edge solutions at ValConnect 2024 Europe, its annual European user conference to be held in Lisbon, Portugal.
ValGenesis and Adryan have strengthened their capabilities to assist life sciences companies meet stringent ISO, FDA, and EU regulatory requirements for quality and safety in drug development and manufacturing.
April
DynaCompliance helps life sciences companies integrate the latest digital technologies and data-driven approaches into drug development, manufacturing, and validation processes, through comprehensive compliance and validation solutions.
A pioneer in scientific research for complex and devastating diseases, the company is advancing a pipeline of potential critical drug therapies across neurology, neuropsychiatry, specialized immunology, and rare diseases.